title: Efinaconazole in the treatment of onychomycosis.
abstract: Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis.
authors.affiliation: Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.
authors.forename: Shari R
authors.initials: SR
authors.lastname: Lipner
authors.affiliation: Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.
authors.forename: Richard K
authors.initials: RK
authors.lastname: Scher
keywords: Jublia; efinaconazole; fungal infection; nail infection; onychomycosis